The Fundamental Place of Pap Test in Iran, Does Primary HPV-Genotyping Seem Cost-Effective in Replace? A Cohort Study
- PMID: 40376076
- PMCID: PMC12080934
- DOI: 10.4103/ijpvm.ijpvm_283_23
The Fundamental Place of Pap Test in Iran, Does Primary HPV-Genotyping Seem Cost-Effective in Replace? A Cohort Study
Abstract
Background: Human papillomavirus (HPV) is a known risk factor for cervical cancer, and currently, primary HPV typing is recommended for screening instead of cervical cytology. However, there are limited studies on the prevalence of HPV in Iran.
Methods: This cross-sectional study evaluated the liquid-based cervical smears of 700 women with no history of HPV vaccination and cervical dysplastic disease from 2017 to 2020 in Isfahan, Iran. Here, we compare the prevalence of HPV genotypes using COBAS with Pap smear cytology results in evaluating the most appropriate cervical cancer screening test.
Results: The prevalence of HPV infection was 23.3%, including 8.7% with HPV 16/18 and 14.6% with other HR (high-risk) HPVs. In cytology reports, 8 out of 16 individuals with high-risk lesions were negative for any type of HPV; on the other hand, there were 129 HR HPV-positive patients out of 570 negative or low-risk Pap smear results.
Conclusions: It assumed that there is no superiority for HPV genotyping over cytology or vice versa in detecting high-risk patients for cervical cancer; as only 26.8% of women with HPV show abnormal cytology; and from those with normal cytology, 17.9% were positive for HR HPV.
Keywords: Human papillomavirus viruses; Pap smear; mass screening; uterine cervical neoplasms.
Copyright: © 2025 International Journal of Preventive Medicine.
Conflict of interest statement
There are no conflicts of interest.
Similar articles
-
Pap Cytology and Human Papillomavirus (HPV) Genotypes in Western Romania: A Retrospective Analysis.Cureus. 2024 Jul 30;16(7):e65720. doi: 10.7759/cureus.65720. eCollection 2024 Jul. Cureus. 2024. PMID: 39211696 Free PMC article.
-
The prevelance of human papillomavirus (HPV) genotypes detected by PCR in women with normal and abnormal cervico-vaginal cytology.Ginekol Pol. 2018;89(2):62-67. doi: 10.5603/GP.a2018.0011. Ginekol Pol. 2018. PMID: 29512809
-
Assessing national cervical cancer screening guidelines: Results from an HIV testing clinic also screening for cervical cancer and HPV in Soweto, South Africa.PLoS One. 2021 Jul 30;16(7):e0255124. doi: 10.1371/journal.pone.0255124. eCollection 2021. PLoS One. 2021. PMID: 34329334 Free PMC article.
-
Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.Sex Health. 2010 Sep;7(3):376-82. doi: 10.1071/SH10022. Sex Health. 2010. PMID: 20719230 Review.
-
Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095. Vaccine. 2012. PMID: 23199969 Review.
References
-
- Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–53. - PubMed
-
- Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20:556–63. - PubMed
-
- Khodakarami N, Farzaneh F, Yavari P, Akbari ME. Cervical cancer screening: Recommendations for muslim societies. Asian Pacific J Cancer Prev. 2016;17:239–47. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials